[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cppd---calcium-pyrophosphate-deposition-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cppd---calcium-pyrophosphate-deposition-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,75],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100581832","phase-2-colchicine-to-reduce-your-symptoms-and-lower-levels-of-inflammation-zeroing-in-on-effective-cppd-disease-treatment-100581832",false,"NCT06855433","Colchicine to Reduce Your SympToms And Lower Levels of Inflammation, Zeroing in on Effective CPPD Disease Treatment","A Randomized, Double-Blind, Multi-Site Placebo Controlled Trial of Colchicine in Calcium Pyrophosphate Deposition Disease","CRYSTALLIZE","Inclusion Criteria:\n\n* Provide written informed consent\n* Fulfill ACR\u002FEULAR 2023 CPPD classification criteria\n* Acute or chronic joint inflammation in the past 3 months, not attributable to another condition\n* Pain visual analog scale (pain VAS) \\>=30 at screening\n\nExclusion Criteria:\n\n* age \\\u003C40 years\n* chronic diarrhea\n* gout, rheumatoid arthritis, or psoriatic arthritis\n* cirrhosis\n* ongoing use of colchicine and unwilling to undergo a 30-day wash-out period (note: patients using colchicine at screening can enroll if they agree to a 30-day wash-out before randomization)\n* pregnant or breast-feeding\n* use of methotrexate, hydroxychloroquine, or anakinra in the past month\n* use of oral glucocorticoid in the past week\n* use of strong CYP3A4 inhibitors per FDA package insert for colchicine\n* use of P-glycoprotein inhibitors per FDA package insert for colchicine\n* known allergy to colchicine\n\nScreening labs with any of the following:\n\n* hemoglobin \\\u003C 11.5 g\u002FdL\n* WBC \\\u003C3 x 10\\^9\u002FL\n* platelets \\\u003C110 x10\\^9\u002FL\n* creatinine clearance (CrCl) \\\u003C30 mL\u002Fmin\n* ALT or AST \\>3x upper limit of normal (ULN)","ALL","40 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if colchicine reduces levels of proteins indicating inflammation in the blood in individuals with calcium pyrophosphate deposition (CPPD) disease. The trial will also test the effect of colchicine on joint symptoms in CPPD disease. The main questions it aims to answer are:\n\n* Does colchicine reduce the level of interleukin 18 (IL-18) in the blood of individuals with CPPD disease?\n* Does colchicine reduce pain scores in individuals with CPPD disease?\n\nResearchers will compare colchicine once daily to a placebo (a look-alike pill that contains no drug) to see if colchicine works to treat CPPD disease.\n\nParticipants will:\n\n* Take colchicine or a placebo every day for 6 months\n* Visit the clinic 3 times in 6 months for joint examinations, surveys, and blood tests. Each visit will last 2-3 hours.\n* Speak on the telephone with researchers for about 4 times over 6 months. Each phone call will last about 5 minutes.",[27],"CPPD - Calcium Pyrophosphate Deposition Disease",[29,30,31,32],"colchicine","CPPD disease","calcium pyrophosphate","pseudogout","NOT_YET_RECRUITING","2026-05-27",{"date":36,"type":37},"2026-05-29","ACTUAL",{"date":39,"type":21},"2026-07-01",{"date":41,"type":21},"2030-09-30",{"name":43,"class":44},"Brigham and Women's Hospital","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100631704","the-orienting-study-100631704","NCT07504146","The Orienting Study","The Natural History Of Calcium Pyrophosphate Deposition And Gout: An Observational Clinical And Imaging Study - The Orienting Study","ORIENTING","The inclusion criteria for CPPD patients are:\n\n* Patients diagnosed with CPPD disease according to the ACR\u002FEULAR 2023 classification criteria.\n* Patients with evidence of asymptomatic CPPD on US or X-rays (not meeting the classification criteria) according to validated imaging definitions.\n* Aged older than 18 years.\n* Able to provide informed consent, according to requirements of local IRB\u002Fethics committee.\n\nThe inclusion criteria for gout patients are:\n\n* Patients diagnosed with gout according to the ACR\u002FEULAR 2015 classification criteria.\n* Aged older than 18 years.\n* Able to provide informed consent, according to requirements of local IRB\u002Fethics committee.\n\nThe inclusion criteria for disease controls are:\n\n* A diagnosis of OA according to ACR classification criteria\n* No evidence of uric acid or calcium pyrophosphate deposits on US\n* Uric acid \\\u003C 6 mg\u002FdL\n* Aged older than 18 years.\n* Able to provide informed consent, according to requirements of local IRB\u002Fethics committee\n\nThe exclusion criteria for gout\u002FCPPD patients are:\n\n* Known history of other inflammatory arthropathies\n* Unable to provide informed consent, according to requirements of local IRB\u002Fethics committee.\n\nThe exclusion criteria for disease controls are:\n\n* Known history of other inflammatory arthropathies\n* Unable to provide informed consent, according to requirements of local IRB\u002Fethics committee.","18 Years",{"count":55,"type":21},450,"OBSERVATIONAL","This study at IRCCS Galeazzi - Sant'Ambrogio Hospital involves patients with gout, CPPD, and osteoarthritis as a control group. Patients will receive routine care with regular clinical, laboratory, and imaging assessments every six months, alongside urgent visits as needed. The study aims to understand crystal deposits in joints and blood vessels and monitor their progression over time, assessing how these deposits respond to standard treatments and if they are associated with cardiovascular complications. Data will be collected from medical records over a follow-up period of up to 10 years, offering long-term insights into disease impact and treatment effectiveness.",[27,59],"Gout",[61,59,62,63],"CPPD","Osteoarthritis","Ultrasound","RECRUITING","2026-03-25",{"date":67,"type":37},"2026-03-31",{"date":69,"type":37},"2024-10-30",{"date":71,"type":21},"2039-10-30",{"name":73,"class":44},"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio",1,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":74},"100586975","the-osteoarticular-manifestations-in-patients-with-gitelman-syndrome-100586975","NCT06922370","The Osteoarticular Manifestations in Patients With Gitelman Syndrome","CPPD and more","Inclusion Criteria:\n\n* Patients confirmed with Gitelman Syndrome\n\nExclusion Criteria:\n\n* Patients with other confounding situations such as Bartter Syndrome, hyperparathyroidism",{"count":83,"type":21},120,"Patients with clinically and genetically confirmed Gitelman Syndrome are screened for CPPD, and the clinical and radiographic manifestations are collected and analyzed.",[86,27],"Gitelman Syndrome","2025-04-03",{"date":89,"type":37},"2025-04-10",{"date":91,"type":37},"2021-11-01",{"date":93,"type":21},"2025-12-01",{"name":95,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University"]